{
  "guideline": {
    "id": "PA166262261",
    "name": "Annotation of CPIC Guideline for pitavastatin and SLCO1B1",
    "source": "CPIC",
    "version": 6,
    "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166262261",
    "relatedChemicals": [
      {
        "id": "PA142650384",
        "name": "pitavastatin",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA134865839",
        "name": "solute carrier organic anion transporter family member 1B1",
        "symbol": "SLCO1B1"
      }
    ],
    "recommendation": true
  },
  "recommendations": [
    {
      "id": "PA166298453",
      "name": "Recommendation PA166298453",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA142650384",
          "name": "pitavastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061055,
        "html": "<p>Prescribe ≤1mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. If dose &gt;1mg needed for desired efficacy, consider an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pitavastatin plus non-statin guideline directed medical therapy)(PMID: 30423391).</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.</p>\n"
      },
      "implications": [
        "SLCO1B1: Increased pitavastatin exposure as compared to normal and decreased function which may translate to increased myopathy risk."
      ],
      "lookupKey": {
        "SLCO1B1": "Poor Function"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298454",
      "name": "Recommendation PA166298454",
      "population": "general",
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA142650384",
          "name": "pitavastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061056,
        "html": "<p>No recommendation</p>\n"
      },
      "implications": [
        "SLCO1B1: n/a"
      ],
      "lookupKey": {
        "SLCO1B1": "Indeterminate"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298449",
      "name": "Recommendation PA166298449",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA142650384",
          "name": "pitavastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061051,
        "html": "<p>Prescribe desired starting dose and adjust doses based on disease-specific guidelines.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function and ancestry should be evaluated prior to initiating a statin.</p>\n"
      },
      "implications": [
        "SLCO1B1: Typical myopathy risk and statin exposure"
      ],
      "lookupKey": {
        "SLCO1B1": "Increased Function"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298450",
      "name": "Recommendation PA166298450",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA142650384",
          "name": "pitavastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061052,
        "html": "<p>Prescribe desired starting dose and adjust doses based on disease-specific guidelines.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function and ancestry should be evaluated prior to initiating a statin.</p>\n"
      },
      "implications": [
        "SLCO1B1: Typical myopathy risk and statin exposure"
      ],
      "lookupKey": {
        "SLCO1B1": "Normal Function"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298452",
      "name": "Recommendation PA166298452",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA142650384",
          "name": "pitavastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061054,
        "html": "<p>Prescribe ≤ 2mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;1mg. If dose &gt;2mg needed for desired efficacy, consider an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pitavastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.</p>\n"
      },
      "implications": [
        "SLCO1B1: Increased pitavastatin exposure as compared to normal function which may translate to increased myopathy risk"
      ],
      "lookupKey": {
        "SLCO1B1": "Decreased Function"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298451",
      "name": "Recommendation PA166298451",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA142650384",
          "name": "pitavastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061053,
        "html": "<p>Prescribe ≤ 2mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;1mg. If dose &gt;2mg needed for desired efficacy, consider an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pitavastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.</p>\n"
      },
      "implications": [
        "SLCO1B1: Increased pitavastatin exposure as compared to normal function which may translate to increased myopathy risk"
      ],
      "lookupKey": {
        "SLCO1B1": "Possible Decreased Function"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    }
  ],
  "citations": [
    {
      "pmid": "35152405",
      "title": "The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms.",
      "authors": [
        "Cooper-DeHoff Rhonda M",
        "Niemi Mikko",
        "Ramsey Laura B",
        "Luzum Jasmine A",
        "Tarkiainen E Katriina",
        "Straka Robert J",
        "Gong Li",
        "Tuteja Sony",
        "Wilke Russell A",
        "Wadelius Mia",
        "Larson Eric A",
        "Roden Dan M",
        "Klein Teri E",
        "Yee Sook Wah",
        "Krauss Ronald M",
        "Turner Richard M",
        "Palaniappan Latha",
        "Gaedigk Andrea",
        "Giacomini Kathleen M",
        "Caudle Kelly E",
        "Voora Deepak"
      ],
      "journal": "Clinical pharmacology and therapeutics",
      "year": 2022
    }
  ],
  "version": "2023-12-19-10-38"
}